Skip to Content

T315I BCR-ABL Mutation Analysis

Quantitative

Indication

For monitoring of the levels of the Thr to Ile mutation at codon 315 (T315I) of the BCR-ABL kinase seen in CML patients who have developed resistance to imatinib or other kinase inhibitors.

Methodology

PCR-based pyrosequencing of RNA is performed to examine mutational status of codons 315 of the BCR-ABL fusion transcript. The ratio of mutated/unmutated PCR product at codon 315 is reported.

Test Parameters

CML clone must comprise at least 5% of the cells in the sample for accurate assessment. Levels are quantitative with approximately 5-10% variability.

Turnaround Time

Five to seven days

Sample Requirements

  • 10 mls peripheral blood (PB) in purple top tube (EDTA Vacutainer), sent on wet ice

    or
  • 2-5 ml of bone marrow aspirate (BM), sent on wet ice

    or
  • 10 µg of purified RNA, sent on dry ice

    or
  • 5-10 µg of cDNA, sent on dry ice

CPT Codes

81401

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.


© 2014 The University of Texas MD Anderson Cancer Center